Actos Cancer Update

Actos Cancer: For invasive bladder cancer, chemotherapy is sometimes given before a cystectomy. Sometimes it is given afterward. Sometimes it is not given at all. It depends entirely on the type of tumor you have, where it may have spread, and whether you have another medical condition that might make it difficult for you to tolerate chemotherapy. Very advanced age can also be a factor in deciding whether che­motherapy is appropriate.

The choice of drugs used to treat invasive bladder cancer is similar to the choice in advanced or metastatic disease, and we will cover that in chapter 6. If you have invasive uro­thelial carcinoma, you will probably undergo chemotherapy, because this type of cancer is responsive to either radiother­apy or surgery with chemotherapy, and many studies have examined this type of cancer treatment. If you have been diagnosed with squamous cell can­cer or adenocarcinoma, the outcome for chemotherapy is not so clearly defined. Most physicians don’t recommend chemotherapy as standard treatment in conjunction with cystectomy for these types of cancer. It is, however, quite reasonable for your team to suggest that you look into a clinical trial (e.g., one that is exploring the use of chemo­therapy) if you have been diagnosed with squamous cell or adenocarcinoma.

For more information on Actos Cancer follow us on our RSS Feeds.

For invasive urothelial carcinoma, most of the informa­tion from clinical trials has been obtained from patients who were initially given chemotherapy by intravenous injection and who then went on to cystectomy or to definitive radio­therapy. Most of the reported trials indicate that the use of single chemotherapy drugs does not have an extensive beneficial effect, but that the use of combinations of three or four chemotherapy drugs can shrink the bladder cancer in about 70 percent of cases. The drugs can also improve the cure rate and length of survival.

For you as a patient, the information gleaned from these clinical trials means that if you have urothelial cancer, your doctors are likely to recommend treatment that includes a cocktail of several carefully targeted chemotherapy drugs as well as cystectomy or radiotherapy. With some cancers, such as breast cancer, it is fairly standard practice to give several doses of chemotherapy after surgery, especially for tumors with high-risk pathologi­cal features, such as lymph-node involvement. We know of six studies that have examined the question of when che­motherapy should be administered for best outcome with bladder cancer, but the results are somewhat inconclusive about whether chemotherapy is most effective if given before or after surgery.

A large randomized trial is in progress in Europe to study whether intravenous chemotherapy after cystectomy improves the cure rate. Until the results of that study are available, most medical teams recommend consideration of first-line chemotherapy, followed by cystectomy, for deeply invasive bladder cancer. Sometimes a cystectomy reveals a cancer that is deeper or more extensive than had been expected; in that situation, the urologist or oncologist will usually discuss the benefits and drawbacks of using chemo­therapy after surgery (called adjuvant chemotherapy), typi­cally with the same drugs that would have been given before surgery.

Information from other sources on Actos Cancer

Following are descriptions of some common chemother­apy combinations. This is not an exhaustive list. Talk with your doctor about your treatment plan. Remember that not all people experience all side effects. Your general health, age, other drugs you might be taking, and the dosage of the chemotherapy drugs may affect what side effects you experience. Many side effects are unpleasant, but they are temporary, and the severity of effects is variable. Some side effects are more serious, and you should talk with your med­ical team about them.

Our use of the term or terms Actos Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Cancer visit our site often.

Actos Cancer

Actos Attorney

Actos Attorney 12/15/2011: Ureteral injury may occur when a tumor covers the ureter in the bladder. The ureter may be obscured by a bladder tumor, and the urologist may inadvertently resect it along with the tumor. In general, cutting current to remove a bladder tumor does not usually lead to long lasting problems as compared to cauterization, which is more likely to cause permanent blockage or obstruction of the ureter. If the urologist is working in the area of the ureter, he should avoid cauterization as much as possible. He may ask the anesthetist to inject an intravenous coloring agent which will turn the urine blue and allow visualization of the ureter. If he knows a ureter may be in jeopardy, he may insert a stent (a small plastic tube that traverses the ureter) for several weeks to allow the ureter to heal in an open fashion.

For more information on Actos Attorney follow us on our RSS Feeds.

Our use of the Terms Actos Lawsuit, Actos Cancer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

 

http://www.seedol.com